Home | Medical-Newswire.Com:
(Medical-NewsWire.com, September 20, 2012 ) New York, NY -- Advanced Medical Isotope Corporation (ADMD) is already a US-based manufacturer and distributor of medical isotopes and is also developing key technologies that may offer a superior alternative to the current standard of care for battling cancer with nuclear medicine.
In a Thursday report, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies key point for optimism regarding the company and examines its speculative potential as an investment. Full report available at: http://vfcsstockhouse.com/blog/article/-advanced-medical-isotope-corporation-expanded-distribution-and-radiogel-technology-hold-the-keys-to-the-future
Advanced Medical Isotope Corporation (ADMD) has - through key partnerships, expanding distribution channels and the acquisition of a license to a novel cancer-fighting technology - well positioned itself to become a growth player in the field of nuclear medicine, specifically in the field of the production and distribution of medical isotopes. Medical isotopes are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage and treat diseases and are deemed a hot item whenever discussed because of the geopolitical implications of non-nuclear nations attempt to enrich uranium for - ahem - solely medical purposes.
Advanced Medical is one of only a few companies in the United States manufacturing and distributing such isotopes and it's likely that business could quickly hit a growth spurt - not only through the company's own indigenous expansion and distribution efforts, but also because of the growing desire of the medical community in the US to use 'home grown' nuclear materials, not to mention increasing regulation that may force the community to do so anyway.
AMIC already offers a broad variety of isotopes and, as outlined in a recent quarterly report, is looking to expand its 'pipeline' of product offerings for its distribution network of customers that include - but is not limited to - national laboratories, hospitals, research facilities and universities.
Many of the company's isotopes are put to use through molecular imaging, or Positron Emission Tomography (PET), which enables Doctors and medical professionals to identify cancerous condictions well before detection means that search for tumor mass. Some of the radiopharmaceutical products based on the medical isotopes are also used in the early detection of certain cardiovascular indications and, as mentioned above, the demand for such products is growing, not shrinking. According to numbers identified in a recent company presentation and credited to the World Nuclear Association, the use of medical isotopes is growing at an annual rate of 10%.
That places AMIC right in the middle of a potential growth boom.
While production and distribution may encompass the company's core business model, AMIC is moving heavily into the field of treatment, too. The process of placing radioactive "seeds" in or near a cancerous tumor is known as brachytherapy, and AMIC is developing a pipeline based on such technology to augment the already-growing core business plan.
In April, the company acquired a license and numerous relating patents to an injectible radiogel technology that could have a significant impact on the next generation of fighting cancer. Using the radiogel technology doctors could deliver Yttrium-90 "microspheres" directly into cancerous tissue. Because the injectible polymer turns solid and holds the microspheres in place, there is little to no threat of any radiation escaping and damaging surrounding tissue. As described by Dr. Alan Walter, Chair of the AMIC Scientific Committee, in a presentation available on the company's home page, such a technology could be termed as using "smart bullets" to target cancerous cells.
Yttrium-90, in the form of Polymer seeds, is an already-established medical isotope with numerous applications in existing cancer treatment and has demonstrated effectiveness in combating head, neck, liver and prostate cancers, according to an above-linked company presentation. The radiogel application of Yttrium-90 could potentially 'storm the scene' in treating numerous cancer types with the intent of targeting those tumors in the hard-to-get to areas of the body that eliminates surgery as an option.
Both the Polymer seeds and the acquired the radiogel technology significantly boost the diversity of AMIC, offering a targeted path to enter the realm of caner treatment to augment the production, sales and distribution channels of its isotopes.
It's possible, based on previous expectations, that the Brachytherapy pipeline could hit market within a couple of years. At that point AMIC could either move forward with commercialization on its own or out-license the technology to someone else and use that revenue stream of royalties to fund the expansion of the core business.
Shares were up by eight percent on Wednesday, although volume was very light. That said, volume has been picking up significantly over the past few months and has tripled already once this year. Volume has also stormed in after the company's more relevant press releases, indicating that there are investors on the sidelines who either wait to play a quick trade or may be taking a 'wait and see' approach to playing this still-speculative stock.
Should the potential of the AMIC distribution network continue to expand and meet the growing demand for nuclear medicine - and should the polymer seeds and radiogel technology also hit market with momentum - then it's likely that the current ADMD share price could start to move. Currently, shares consistently trade for a few pennies above the twenty cents mark, give or take.
Based on the potential of the developing technology, already-available products and future product offerings, the current ADMD trading levels could serve as an opportune accumulation period to those looking at the risk/reward profile for the future. The current market cap of still under twenty million indicates that many investors are still unconvinced, but when searching for potential payoff picks on the bulletin board stocks, it pays off to be in while the stock is still moving along relatively unnoticed, as the best percentage gains to be had in any run start with being in place before the run starts.
That said, the stock market is risky business and there are no sure things, that's why it's up to each investor to conduct his or her own DD and invest accordingly.
Still a developing story worth monitoring.
Disclosure: No position.
Follow ADMD developments and other small cap stocks at VFCsStockHouse.com
Contact VFC's Stock House: email@example.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights and opinions into broader-market news. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and make informed and well thought-out investment decisions. For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Vertex Pharma's lung disorder therapy wins FDA nod
2 Jul 2015 at 9:59am
Vertex Pharmaceuticals Inc's unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company's reach to the most common form of genetic mutation responsible for cystic fibrosis. Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for patients aged 12 and above, the U.S. Food and Drug Administration said on Thursday. The combination treats the most common F508del mutation, while Kalydeco alone treats cystic fibrosis patients with a different mutation.
No need for new rules to protect butterflies from GM pollen: EU report
2 Jul 2015 at 9:49am
By Alexander Saeedy BRUSSELS (Reuters) - European food safety officials found there was no need to widen buffer zones around genetically modified (GM) crops even though research shows that pollen from GM maize, which can travel kilometres further than previously thought. The buffer zones to protect vulnerable species, such as butterflies, have been part of heated debate in Europe about the safety of GM crops, which the producers say are entirely safe and environmentalists say are a serious threat to biodiversity. Scientific research has found caterpillars of some butterfly species can be harmed by GM pollen.
Court clears German safety body in breast implant scare
2 Jul 2015 at 9:46am
A French appeals court on Thursday cleared German safety standards body TUV of liability in a faulty breast implant scandal, meaning hundreds of women will have to pay back damages they received. The ruling overturns a decision by a lower French court in 2013 which had found TUV liable and ordered it to pay millions of euros in compensation to victims and distributors. TUV certified that implants made by French firm Poly Implant Prothese (PIP) conformed to safety rules -- even though they were subsequently found to contain substandard, industrial-grade silicone gel.
Thousands evacuated after freight train derails, catches fire, in Tennessee
2 Jul 2015 at 9:44am
Matt Farr, his brother and their parents woke up to the news and grabbed a change of clothes at about 8:30 a.m. ET before heading to a nearby animal center to drop off their Yorkie dog, Rosie. Farr, 21, said the four Maryville residents would stay in two rooms at a nearby hotel until the evacuation is lifted. "We didn't think we'd be there that long, but now it's starting to look like we may be there for a couple days," he told Reuters via telephone from the animal center.
What A Music Festival Taught Me About Periods
2 Jul 2015 at 9:37am
8:00 a.m.Stretch my arms and legs, crack open my eyes. Where the hell am I? I wonder. The sun is shining from above, and I can feel a lumpy mass of blanket below. I'm already sweating. Why is it so hot in here? Then I realize that I am not in my air conditioned bedroom in Los Angeles; I'm in a tent on a field in Manchester, Tennessee. I'm here...
HIV stigma, fear linger in UK as infection rates continue to rise
2 Jul 2015 at 9:27am
By Kieran Guilbert LONDON (Thomson Reuters Foundation) - Rich paces the cramped, dimly-lit living room in despair, fearful of losing his friends, family and career as he struggles with the realisation that he has HIV. One of the first plays about AIDS, "As Is" revolves around a dysfunctional young gay couple whose lives are thrown into chaos by the HIV epidemic that swept through New York in the early 1980s. For director Andrew Keates, who was diagnosed with HIV during a production of the play in 2013, the shame, fear and misinformation surrounding the incurable virus in "As Is" still resonate in Britain more than 30 years later.
Insulin pump may cut risk of heart disease deaths with diabetes
2 Jul 2015 at 9:01am
By Roxanne Nelson (Reuters Health) - People with type 1 diabetes must control their blood sugar with insulin, but getting it automatically from an implanted pump may also help to stave off death from heart disease, according to a large Scandinavian study. Among more than 18,000 type 1 diabetics in Sweden followed over time, those with an insulin pump were about half as likely to die of heart-related causes, and 25 percent less likely to die of any cause, compared to those who injected themselves with insulin many times a day. ?Our study shows that treatment with an insulin pump almost halves the risk of cardiovascular mortality,? said lead study author Dr. Isabelle Steineck from Aarhus University Hospital in Denmark.
Anthem, Cigna in new round of talks: source
2 Jul 2015 at 8:55am
(Reuters) - U.S. health insurer Cigna Corp has had its first meetings with competitor Anthem Inc after it rebuffed Anthem's $47 billion merger proposal last month, a person familiar with the matter said on Thursday. The talks come as both Cigna and rival Aetna Inc consider the possible acquisition of smaller player Humana Inc , people familiar with the matter have said previously. Cigna and Anthem declined to comment.
Congo and WHO investigate possible Ebola outbreak
2 Jul 2015 at 8:47am
Health officials in Democratic Republic of Congo are investigating a possible outbreak of Ebola in a village, the government and the World Health Organization (WHO) said on Thursday. Eugene Kabambi, a spokesman for WHO in Congo, said the suspected outbreak was in the village of Masambio in Bandundu province, more than 400 km (250 miles) northeast of the capital Kinshasa. A three-month outbreak that killed 49 people late last year in the remote forests of northwestern Congo was not related to the West African epidemic.
Healthcare students often uninformed about smoking dangers, cessation
2 Jul 2015 at 8:38am
By Janice Neumann (Reuters Health) - Nursing and physiotherapy students may be smoking less than they were a decade ago, but they also know less about the health consequences of tobacco and how to help patients quit the habit, a new study from Spain suggests. ?The fact that less than 40 percent of students knew that smoking caused emphysema and only 10 percent identified smoking as a major cause of coronary artery disease in 2013 is quite astonishing,? said Dr. Michael Steinberg, who heads the Tobacco Dependence Program at Rutgers Cancer Institute of New Jersey. ?Knowledge and attitudes have barely changed despite the years and the laws,? said Beatriz Ordas, a staff nurse at the University Hospital of Leon, who led the new research.
Civilians in Yemen's Aden struggle to survive fighting, shortages: Red Cross
2 Jul 2015 at 8:26am
Lamon, a Swiss national, worked in Aden from January 2014 and stayed months into the Houthi military push on the city that prompted an Arab military intervention on March 26. A Saudi-led coalition of Gulf Arab countries has been bombing the Iran-allied Houthis for three months to try to restore Yemen's exiled government of President Abd-Rabbu Mansour Hadi. Saudi Arabia, determined to thwart any arms deliveries to the Houthis, has imposed a near total blockade on a country heavily reliant on imports.
'Frightened' Child Restrained at Dentist Office, Family Says
2 Jul 2015 at 8:26am
Several parents in Georgia are critical of a device being used to restrain their children during dental procedures.
Mindfulness and the Average Smartphone: Technology for Calm Instead of Chaos
2 Jul 2015 at 8:19am
The modern, technology driven world often seems to make people feel distracted and stressed. In my field, child development research bluntly shows under-monitored technology influences children for the worse. But technology is simply a tool, and how it impacts our lives depends entirely on how we use it. As with any part of our life, we can...
Electrolux CEO seeks to rescue GE deal after legal blow
2 Jul 2015 at 8:00am
The head of Sweden's Electrolux said he believed a $3.3 billion deal to buy the GE Appliances business could be salvaged after the United States moved to block it. The U.S. Justice Department filed a lawsuit on Wednesday to stop the purchase, arguing that it would hurt competition in the market for cooking appliances. Electrolux CEO Keith McLoughlin wants to preserve as much of it as he can.
California cancer patient with amnesia identified by sister: NBC
2 Jul 2015 at 7:53am
(Reuters) - A woman with amnesia who has been undergoing cancer treatments since she was found semiconscious in Southern California has been identified by her sister after turning to social media in a bid to rekindle her memory and find her family, an NBC affiliate in San Diego reported on Thursday.